Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 05, 2021

SELL
$12.91 - $23.83 $14,201 - $26,212
-1,100 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$8.0 - $28.5 $8,800 - $31,350
1,100 New
1,100 $12,000

Others Institutions Holding HGEN

About HUMANIGEN, INC


  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Glassman Wealth Services Portfolio

Follow Glassman Wealth Services and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

News

Stay updated on Glassman Wealth Services with notifications on news.